Akbulut Sami, Yagin Fatma Hilal, Sahin Tevfik Tolga, Garzali Ibrahim Umar, Tuncer Adem, Akyuz Musap, Bagci Nazlican, Barut Bora, Unsal Selver, Sarici Kemal Baris, Saritas Serdar, Ozer Ali, Bentli Recep, Colak Cemil, Bayindir Yasar, Yilmaz Sezai
Department of Surgery and Liver Transplant Institute, Inonu University Faculty of Medicine, Malatya 44280, Turkey.
Department of Biostatistics and Medical Informatics, Inonu University Faculty of Medicine, Malatya 44280, Turkey.
J Clin Med. 2023 Jul 3;12(13):4466. doi: 10.3390/jcm12134466.
In liver transplant (LT) recipients, immunosuppressive therapy may potentially increase the risk of severe COVID-19 and may increase the mortality in patients. However, studies have shown conflicting results, with various studies reporting poor outcomes while the others show no difference between the LT recipients and healthy population. The aim of this study is to determine the impact of the COVID-19 pandemic on survival of LT recipients.
This is a retrospective cohort study analyzing the data from 387 LT recipients diagnosed with COVID-19. LT recipients were divided into two groups: survival ( = 359) and non-survival ( = 28) groups. A logistic regression model was used to determine the independent risk factors for mortality. Machine learning models were used to analyze the contribution of independent variables to the mortality in LT recipients.
The COVID-19-related mortality rate in LT recipients was 7.2%. Multivariate analysis showed that everolimus use ( = 0.012; OR = 6.2), need for intubation ( = 0.001; OR = 38.4) and discontinuation of immunosuppressive therapy ( = 0.047; OR = 7.3) were independent risk factors for mortality. Furthermore, COVID-19 vaccination reduced the risk of mortality by 100 fold and was the single independent factor determining the survival of the LT recipients.
The effect of COVID-19 infection on LT recipients is slightly different from the effect of the disease on the general population. The COVID-19-related mortality is lower than the general population and vaccination for COVID-19 significantly reduces the risk of mortality.
在肝移植(LT)受者中,免疫抑制治疗可能会增加患重症 COVID-19 的风险,并可能增加患者的死亡率。然而,研究结果相互矛盾,各种研究报告的结果不佳,而其他研究则表明 LT 受者与健康人群之间没有差异。本研究的目的是确定 COVID-19 大流行对 LT 受者生存的影响。
这是一项回顾性队列研究,分析了 387 名被诊断为 COVID-19 的 LT 受者的数据。LT 受者分为两组:生存组(= 359)和非生存组(= 28)。使用逻辑回归模型确定死亡的独立危险因素。使用机器学习模型分析自变量对 LT 受者死亡率的贡献。
LT 受者中与 COVID-19 相关的死亡率为 7.2%。多变量分析表明,使用依维莫司(= 0.012;OR = 6.2)、需要插管(= 0.001;OR = 38.4)和停用免疫抑制治疗(= 0.047;OR = 7.3)是死亡的独立危险因素。此外,COVID-19 疫苗接种将死亡风险降低了 100 倍,是决定 LT 受者生存的唯一独立因素。
COVID-19 感染对 LT 受者的影响与该疾病对一般人群的影响略有不同。与 COVID-19 相关的死亡率低于一般人群,COVID-19 疫苗接种显著降低了死亡风险。